Частковий час тромбопластину – скринінг вовчакового антикоагулянта (Partial Thromboplastin Time – Lupus Anticoagulant Screen)

Референтні значення:

Діапазон нормального активованого часткового тромбопластину незначно відрізняється між лабораторіями , але зазвичай знаходиться між наступними діапазонами:

  • Повнолітні (вік, 0-5 д) – 25-60 секунд
  • Доношені немовлята (вік, від 6 до 3 міс) – 24-50 секунд
  • Старше 3 місяців,  дорослі – 24-36 секунд

ДЖЕРЕЛА:

  1. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009 Oct. 7(10):1737-40.
  2. Adcock DM, Marlar RA. Activated partial thromboplastin time reagent sensitivity to the presence of the lupus anticoagulant. Arch Pathol Lab Med. 1992 Aug. 116(8):837-40.
  3. Kelsey PR, Stevenson KJ, Poller L. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time–the central role of phosphatidyl serine. Thromb Haemost. 1984 Oct 31. 52(2):172-5.
  4. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb. 4(2):295-306.
  5. Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell’s viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood. 1995 Jul 15. 86(2):617-23.
  6. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M,. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012 Feb 8.
  7. Rauch J, Tannenbaum M, Tannenbaum H, et al. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chem. 1986 Jul 25. 261(21):9672-7.
  8. Triplett DA. Simultaneous occurrence of lupus anticoagulant and factor VIII inhibitors. Am J Hematol. 1997 Nov. 56(3):195-6.
  9. Ginsberg JS, Brill-Edwards P, Johnston M, et al. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood. 1992 Aug 15. 80(4):975-80.
  10. Long AA, Ginsberg JS, Brill-Edwards P, Johnston M, Turner C, Denburg JA. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost. 1991 Nov 1. 66(5):520-4.
  11. Haartmann RC, Conley CL. Studies on the initiation of blood coagulation, III. The clotting properties of canine platelet-free plasma. J Clin Invest. 1952 Jul. 31(7):685-91.
  12. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemost Thromb. 1972. 1:75-95.
  13. Bowie EJ, Thompson JH JR, Pascuzzi CA, Owen CA JR. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med. 1963 Sep. 62:416-30.
  14. Shapiro SS, Thiagarajan P. Lupus Anticoagulants Prog Hemost Thromb. 1982. 6:263.
  15. Beaumont JL. [Acquired hemorrhagic syndrome caused by a circulating anticoagulant; inhibition of the thromboplastic function of the blood platelets; description of a specific test]. Sang. 1954. 25(1):1-15.
  16. Nilsson IM, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant (“antithromboplastin”). Acta Med Scand. 1975 Mar. 197(3):153-9.
  17. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed). 1983 Oct 15. 287(6399):1088-9.
  18. Hughes GR. The anticardiolipin syndrome. Clin Exp Rheumatol. 1985 Oct-Dec. 3(4):285-6.
  19. Gharavi AE, Sammaritano LR, Wen J, Elkon KB. Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J Clin Invest. 1992 Sep. 90(3):1105-9.
  20. García CO, Kanbour-Shakir A, Tang H, Molina JF, Espinoza LR, Gharavi AE. Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with beta 2 GPI. Am J Reprod Immunol. 1997 Jan. 37(1):118-24.
  21. Viard JP, Amoura Z, Bach JF. Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med. 1992 Aug. 93(2):181-6.
  22. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999 Jul. 42(7):1309-11.
  23. [Guideline] Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost. 2014 Mar. 40 (2):163-71.
  24. Moore GW. Commonalities and contrasts in recent guidelines for lupus anticoagulant detection. Int J Lab Hematol. 2014 Jun. 36 (3):364-73.
  25. Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998. 7(1):15-22.
  26. Brey RL, Escalante A. Neurological manifestations of antiphospholipid antibody syndrome. Lupus. 1998. 7 Suppl 2:S67-74.
  27. Gosselin RC, Dwyre DW. Determining the effect of freezing on coagulation testing: comparison of results between fresh and once frozen-thawed plasma. Blood Coagul Fibrinolysis. 2015 Jan. 26 (1):69-74.
  28. Góralczyk T, Iwaniec T, Wypasek E, Undas A. False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome. Blood Coagul Fibrinolysis. 2015 Jun. 26 (4):473-5.

Залишити коментар

Ваша e-mail адреса не оприлюднюватиметься. Обов’язкові поля позначені *